Dateline City:
KENILWORTH, N.J.
Findings to be Presented in Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Malignant Pleural Mesothelioma with KEYTRUDA as Monotherapy and in Combination with Other Treatments
Quality of Life Data from KEYNOTE-024 in First-Line Non-Small Cell Lung Cancer to be Presented in Plenary Session
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new data investigating the use of KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, across multiple
thoracic malignancies, including non-small cell lung cancer (NSCLC),
small cell lung cancer and malignant pleural mesothelioma, will be
presented at the 17th World Conference on Lung Cancer (WCLC)
hosted by the International Association for the Study of Lung Cancer in
Vienna, Austria, Dec.
Language:
English
Contact:
Media Contacts:Pamela Eisele, (267) 305-3558orKim Hamilton, (908) 740-1863orInvestor Contacts:Teri Loxam, (908) 740-1986orAmy Klug, (908) 740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more